GlaxoSmithKline have revealed the sales of shingles vaccine Shingrix have helped them to exceed expectations as they announce the result of their second financial quarter.
For the quarter, turnover increased 7% AER, 5% CER to £7,809 million. CER growth was delivered by vaccines and consumer healthcare. Sales were also up 2% AER but down 1% CER, with HIV sales up 2% CER to £1,209 million.
“Vaccine sales boost Q2 figures for GSK“
Vaccines turnover grew 26% AER, 23% CER to £1,585 million, as previously mentioned primarily driven by growth in sales of Shingrix, and the company’s total operating profit was £1,484 million.
Due to the successful results, GSK has adjusted its earnings per share and have said the new forecast reflects improved operating performance.
Reflecting on the results, GSK’s chief executive officer Emma Walmsley said “despite the loss of exclusivity of Advair, we were still able to deliver good operating performance in Q2. The company remains focussed on strengthening our R & D pipeline, and the positive clinical data we have received so far offers significant opportunities for products in Oncology, HIV and Respiratory areas. Our joint venture with Pfizer should be completed shortly and will lay the foundation for the creation of two great companies.”See all the latest jobs in Consumer